Archives of Medical Research
Volume 41, Issue 3 , Pages 195-200, April 2010

Expression of Two Testis-specific Genes, SPATA19 and LEMD1, in Prostate Cancer

  • Soudeh Ghafouri-Fard

      Affiliations

    • Medical Genetics Department, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Zahra Ousati Ashtiani

      Affiliations

    • Medical Genetics Department, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Bareto Sabah Golian

      Affiliations

    • Sabah Golian Ultrasound Clinic, Tehran, Iran
    • ,
  • Seyyed-Mohammad Hasheminasab

      Affiliations

    • Medical Genetics Department, Tehran University of Medical Sciences, Tehran, Iran
    • ,
  • Mohammad Hossein Modarressi

      Affiliations

    • Medical Genetics Department, Tehran University of Medical Sciences, Tehran, Iran
    • Pasteur Institute of Iran, Tehran, Iran
    • Corresponding Author InformationAddress reprint requests to: Mohammad-Hossein Modarressi, Medical Genetics Department, Tehran University of Medical Sciences, Enghelab Street, Tehran, Iran 1417613151; Phone and Fax: 00982188953005

Received 2 January 2010; accepted 30 March 2010.

(ARCMED-D-10-00004)

Background and Aims

Screening methods for early detection of prostate cancer have some limitations regarding specificity and sensitivity, so there is a continuing search to find new cancer biomarkers. Cancer-testis genes are a group of genes with expression almost limited to testis and different kinds of tumors. Since testis is an immune privileged site, if these genes are expressed in tumors, they can be immunogenic. We undertook this study to find new members of the cancer-testis gene family appropriate for cancer immunotherapy

Methods

We analyzed the expression of six testis-specific genes called ODF1, ODF2, ODF3, ODF4, LEMD1 and SPATA19 in 30 prostate cancer and 25 benign prostate hyperplasia (BPH) samples by RT-PCR and restriction fragment length polymorphism (RFLP).

Results

Of the prostate cancer samples, 10, 10, 23 and 40% showed ODF1, ODF2, LEMD1 and SPATA19 specific bands, respectively, but none of the BPH samples expressed any of these genes. The difference between prostate cancer and BPH groups for LEMD1 and SPATA19 expression was significant. Mean serum PSA level was significantly higher in patients expressing ODF2 than in the other patients.

Conclusions

ODF1, ODF2, SPATA19 and LEMD1 are members of cancer-testis gene family. In addition, LEMD1 and SPATA19 are putative cancer biomarkers and promising targets for active immunotherapy.

Key Words: Cancer testis antigen, Immunotherapy, Prostate cancer, SPATA19, LEMD1, ODF

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0188-4409(10)00075-5

doi:10.1016/j.arcmed.2010.04.003

Archives of Medical Research
Volume 41, Issue 3 , Pages 195-200, April 2010

Article Tools

* Image Usage & Resolution